Publications by authors named "Nizar Bahlis"

100Publications

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.

Eur J Haematol 2020 Sep 1;105(3):274-285. Epub 2020 Jun 1.

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13435DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497066PMC
September 2020

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.

Clin Lymphoma Myeloma Leuk 2020 06 7;20(6):394-399. Epub 2019 Nov 7.

Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.11.005DOI Listing
June 2020

Anti-myeloma potential of ruxolitinib in co-existing JAK2V617F-positive smouldering myeloma and polycythaemia vera.

Br J Haematol 2020 May 20;189(3):e114-e118. Epub 2020 Feb 20.

Tom Baker Cancer Center, Department of Medical Oncology and Hematology, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16533DOI Listing
May 2020

Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.

Leuk Lymphoma 2019 12 13;60(13):3199-3203. Epub 2019 Jun 13.

Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1627537DOI Listing
December 2019

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med 2019 05;380(22):2104-2115

From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La Roche sur Yon (M.T.), CHU de Caen, Caen (M.M.), Department of Clinical Hematology, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris (L.F.), and Department of Hematology, CHU la Miletrie and INSERM CIC 1402, Poitiers (X.L.) - all in France; the Department of Hematology, Mayo Clinic Rochester, Rochester, MN (S.K.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.); Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB (N.B.), and the Division of Medical Oncology, University of Alberta, Edmonton (C.P.V.) - both in Canada; Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom (S.B.); Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia (H.Q.); University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg (H.G.), and the Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (K.W.) - both in Germany; Department of Medicine-Haematology, National University of Ireland, Galway (M.O.); Florida Cancer Specialists and Research Institute, St. Petersburg (J.R.M.); the Department of Hematology-Oncology, Massachusetts General Hospital, Boston (N.R.); Genmab US, Princeton (T.A.), and Janssen Research and Development, Raritan (J.W., R.K.) - both in New Jersey; Janssen Research and Development, Spring House, PA (C.C., C.M.U., M.Q.); Janssen Research and Development, Beerse, Belgium (R.V.R.); and Levine Cancer Institute-Atrium Health, Charlotte, NC (S.Z.U.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1817249
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1817249DOI Listing
May 2019

From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1).

J Med Chem 2019 06 4;62(11):5522-5540. Epub 2019 Jun 4.

Arnie Charbonneau Cancer Institute , University of Calgary , 3280 Hospital Drive NW , T2N 4Z6 Calgary , Alberta , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.9b00455DOI Listing
June 2019

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Nat Commun 2019 04 23;10(1):1911. Epub 2019 Apr 23.

Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365 Clifton Rd. NE, Atlanta, GA, 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-09555-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478743PMC
April 2019

Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.

Leukemia 2019 05 24;33(5):1291-1296. Epub 2019 Jan 24.

Department of Hematology and Medical Oncology, Emory University School of Medicine and the Winship Cancer Institute of Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0374-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891824PMC
May 2019

Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution.

Leuk Lymphoma 2018 08 21;59(8):1920-1926. Epub 2017 Nov 21.

a Department of Medical Oncology and Hematology , Tom Baker Cancer Center , Calgary , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1403026DOI Listing
August 2018

Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.

Clin Lymphoma Myeloma Leuk 2018 01 1;18(1):e69-e75. Epub 2017 Nov 1.

Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650173129
Publisher Site
http://dx.doi.org/10.1016/j.clml.2017.10.009DOI Listing
January 2018

Multiple myeloma cells sent "PAKing"!

Blood 2017 04;129(16):2208-2209

UNIVERSITY OF CALGARY.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2017-02
Publisher Site
http://dx.doi.org/10.1182/blood-2017-02-764662DOI Listing
April 2017

Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.

Ann Hematol 2017 Mar 10;96(3):431-439. Epub 2017 Jan 10.

Department of Medical Oncology and Hematology, Tom Baker Cancer Center, 1331 29th St, NW, Calgary, AB, T2N 4N2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-016-2901-xDOI Listing
March 2017

New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.

Clin Cancer Res 2016 Dec 19;22(24):5959-5965. Epub 2016 Oct 19.

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0184DOI Listing
December 2016

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 10;375(14):1319-1331

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1607751DOI Listing
October 2016

Treatment of Relapsed/Refractory Multiple Myeloma.

Cancer Treat Res 2016;169:169-194

Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-40320-5_10DOI Listing
June 2017

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.

Oncotarget 2016 Sep;7(37):59727-59741

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University and the Emory University School of Medicine, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.10847DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312344PMC
September 2016

Revised International Staging System Applied to Real World Multiple Myeloma Patients.

Clin Lymphoma Myeloma Leuk 2016 09 8;16(9):511-518. Epub 2016 Jun 8.

Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.06.001DOI Listing
September 2016

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.

Blood 2016 08 23;128(5):732-5. Epub 2016 Jun 23.

Biology, University of New Brunswick, Saint John, NB, Canada; Department of Oncology, Saint John Regional Hospital, Dalhousie University and University of New Brunswick, Saint John, NB, Canada.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2016-06-71
Publisher Site
http://dx.doi.org/10.1182/blood-2016-06-716902DOI Listing
August 2016

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 Apr;374(17):1621-34

From University Hospital Hôtel Dieu, Nantes (P.M., C.T.), the Department of Hematology, Institut Paoli-Calmettes, Marseille (A.-M.S.), and the Department of Hematology and Cell Therapy, Hospital Saint Antoine, Paris (L.G.) - all in France; the Department of Haematology and Stem Cell Transplantation, St. István and St. László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary (T.M.); the Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, and St. John's Cancer Center, Lublin, Poland (N.G.); Southern Alberta Cancer Research Institute, University of Calgary, Calgary (N.J.B.), and the Division of Hematology, Department of Medicine, University of Alberta, Edmonton (I.S.) - both in Canada; the Department of Hematology, Skåne University Hospital, Lund University, Lund, Sweden (M.H.); Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (L.P.); the Department of Haematology, Christchurch Hospital, Christchurch (P. Ganly), the Department of Haematology, Palmerston North Hospital, Palmerston North, Manawatu (B.W.B.), the Department of Haematology, Middlemore Hospital, Auckland (S.R.J.), and the Department of Haematology, North Shore Hospital, Auckland (D.R.S.) - all in New Zealand; the Department of Hematology, University Hospital Rigshospitalet, Copenhagen (P. Gimsing); Myeloma Unit, Division of Hematology, University of Turin, Turin (A.P.), and Seràgnoli Institute of Haematology, Bologna University School of Medicine, St. Orsola-Malpighi University Hospital, Bologna (M.C.) - both in Italy; the Division of Hematology, Mayo Clinic, Rochester, MN (S.K., F.K.B.); and Dana-Farber Cancer Institute, Boston (J.P.L., P.G.R.), and Millennium Pharmaceuticals, Cambridge (D.T.B., J.L., A.D.B., A.-M.H., H.V.) - both in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1516282DOI Listing
April 2016

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.

Clin Lymphoma Myeloma Leuk 2016 Jun 29;16(6):e79-84. Epub 2016 Mar 29.

Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.03.005DOI Listing
June 2016

Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight.

Leuk Lymphoma 2016 7;57(3):557-62. Epub 2015 Jul 7.

a Division of Hematology and Hematologic Malignancies, University of Calgary , Calgary AB , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1061189DOI Listing
December 2016

Pinning down myeloma with Pim2 inhibitors!

Blood 2013 Aug;122(9):1534-6

University of Calgary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-07-514091DOI Listing
August 2013

Genomic instability in multiple myeloma: mechanisms and therapeutic implications.

Expert Opin Biol Ther 2013 Jun 19;13 Suppl 1:S69-82. Epub 2013 Jun 19.

University of Calgary, Division of Hematology and Bone Marrow Transplant, Hospital Drive NW, Calgary, AB T2N4N1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2013.814637DOI Listing
June 2013

High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma.

Leuk Lymphoma 2013 Dec 16;54(12):2620-6. Epub 2013 Apr 16.

Departments of Oncology and Medicine, University of Calgary and Tom Baker Cancer Centre , Calgary, AB , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.783211DOI Listing
December 2013

Reovirus modulates autophagy during oncolysis of multiple myeloma.

Autophagy 2013 Mar 15;9(3):413-4. Epub 2013 Jan 15.

Department of Oncology, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/auto.22867DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590261PMC
March 2013

Darwinian evolution and tiding clones in multiple myeloma.

Authors:
Nizar J Bahlis

Blood 2012 Aug;120(5):927-8

University of Calgary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-06-430645DOI Listing
August 2012

Reovirus as a viable therapeutic option for the treatment of multiple myeloma.

Clin Cancer Res 2012 Sep 3;18(18):4962-72. Epub 2012 Jul 3.

Department of Oncology, University of Calgary, Calgary, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-3085DOI Listing
September 2012

Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.

Curr Cancer Drug Targets 2012 Sep;12(7):776-96

Division of Hematology, University of Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/156800912802429337DOI Listing
September 2012

Panobinostat for the treatment of multiple myeloma.

Expert Opin Investig Drugs 2012 May 12;21(5):733-47. Epub 2012 Mar 12.

Division of Hematology and Bone Marrow Transplant, University of Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2012.668883DOI Listing
May 2012

Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.

Biol Blood Marrow Transplant 2012 Feb 27;18(2):295-301. Epub 2011 Jul 27.

Alberta Blood and Marrow Transplant Program, Foothills Hospital, and Tom Baker Cancer Centre, 1331-29th Street N.W., Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2011.07.015DOI Listing
February 2012

Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics.

Leuk Lymphoma 2011 Apr 11;52(4):659-67. Epub 2011 Jan 11.

Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2010.548535DOI Listing
April 2011

pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.

Leuk Lymphoma 2009 Aug;50(8):1276-82

Department of Oncology and Medicine, University of Calgary and Tom Baker Cancer Centre, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190903015628DOI Listing
August 2009

The relationships among physiologic variables, quality of life, and fatigue in patients with multiple myeloma.

Oncol Nurs Forum 2009 Mar;36(2):209-16

Alberta Blood and Marrow Transplant Program, Tom Baker Cancer Centre, Calgary, Canada.

View Article

Download full-text PDF

Source
http://onf.ons.org/onf/36/2/relationships-among-physiologic-
Publisher Site
http://dx.doi.org/10.1188/09.ONF.209-216DOI Listing
March 2009

Preventing and treating chronic disorders using the modified vaccination technique.

Front Biosci (Landmark Ed) 2009 Jan 1;14:3892-8. Epub 2009 Jan 1.

Department of Surgery, University of Calgary Health Sciences Centre, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2741/3498DOI Listing
January 2009

New vaccination technology for endogenous antigen-derived ailments.

IDrugs 2008 Feb;11(2):111-5

Department of Surgery, University of Calgary Health Sciences Centre, 2808 Health Sciences Centre, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada.

View Article

Download full-text PDF

Source
February 2008

O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.

Cancer Chemother Pharmacol 2007 Aug 13;60(3):415-21. Epub 2007 Mar 13.

Developmental Therapeutics Program, CASE Comprehensive Cancer Center and the Division of Hematology/Oncology, Case Western Reserve University, Cleveland, OH 44106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-007-0442-7DOI Listing
August 2007

N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells.

Leuk Lymphoma 2005 Jun;46(6):899-908

University of Calgary, Department of Medicine, Division of Hematology and Hematological Malignancies, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190500080595DOI Listing
June 2005

Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.

Leuk Lymphoma 2003 Dec;44(12):2123-34

Division of Hematology and Oncology, Department of Medicine, Sylvester Cancer Center, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1080/1042819031000116
Publisher Site
http://dx.doi.org/10.1080/1042819031000116652DOI Listing
December 2003

Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells.

Mol Cancer Ther 2003 Nov;2(11):1155-64

Sylvester Cancer Center, Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL 33101, USA.

View Article

Download full-text PDF

Source
November 2003

Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells.

ScientificWorldJournal 2001 9;1:110. Epub 2001 Nov 9.

Department of Microbiology and Immunology, University of Miami School of Medicine, P.O. Box 016960 (R-138), Miami, FL, 33101, USA.

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/tswj/2001/170685/abs/
Publisher Site
http://dx.doi.org/10.1100/tsw.2001.123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083965PMC
November 2001